ALT-836 clinical trials
Also written ALT-836.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses ALT-836 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2009 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses ALT-836 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress SyndromeCompletedPhase 1Altor BioScienceNCT01438853Written as TNX-832How we know
- A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Altor BioScienceNCT01325558Written as ALT-836 in combination with gemcitabineHow we know
- Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress SyndromeCompletedPhase 2Altor BioScienceNCT00879606Written as ALT-836How we know